Bloomberg cites voting during the Food and Drug Administration’s Peripheral and Central Nervous System Advisory Committee Meeting to discuss the use of donanemab for the treatment of Alzheimer’s disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly announces detailed results from Phase 2 SYNERGY-NASH trial
- KO, GOOGL, or TSLA: Which Mega-Cap Stock is the Best Pick?
- FDA Peripheral & Central Nervous System Drigs Committee Meeting
- Early notable gainers among liquid option names on June 7th
- Structure Therapeutics price target raised to $100 from $83 at BMO Capital